As spreads widened—all of 2004’s spread tightening unwound in just one month—and market rates moved upward, the outlook for such investors suddenly looked pretty bleak, and certainly no one wanted to buy new issues. Inevitably some corporates were caught out by the sudden change in sentiment. Some, such as German automotive and defense company Rheinmetall, chose to delay their issues.
But others, including Austrian brickmaker Wienerberger and Swiss pharmaceuticals firm Syngenta, pressed ahead and had to pay up for their decision. They were in the market during the week of April 11, and as investors got more skittish over the prospects of LBOs, the borrowers were forced to include change-of-control covenants in their bonds, which would guarantee investors a put at par in the event of a takeover. For debut issuer Wienerberger, the change-of-control clause was a price worth paying to diversify its funding base away from banks in Austria and Germany. “Even with the change of control, the bond market is still very flexible relative to bank lending,” says Hans Tschuden, CFO of Wienerberger. Tschuden does admit that he wishes his bookrunners, ABN AMRO and Bank Austria Creditanstalt, had warned him of the potential need for a change of control on the €400 million seven-year deal.
Syngenta was less happy to offer the change-of-control covenant as it had an existing EMTN program. But as Domenico Scala, CFO of Syngenta, notes, if a company intends to target UK-based investors, in particular, plans to issue more than €100 million and is a potential LBO candidate, then a change-of-control clause is likely to be necessary to complete a deal.
Of course, market conditions can change dramatically for the better as well as for the worse. Just a month after Wienerberger and Syngenta, BASF and Sanofi-Aventis re-opened the market—albeit on investors’ terms. Double-A-rated BASF realized that real money accounts—pension and mutual funds—had built up cash while the market was closed and were seeking a high-quality home for it.
Double-A-rated Sanofi-Aventis chose to focus even more narrowly on the demands of one group of investors and used its high A1-plus/P1 short-term debt rating to its advantage. Among French corporates outside the banking sector only oil company Total has a similar rating, and consequently money market funds and banks were eager to buy Sanofi-Aventis’s two-year €1 billion FRN.
Since then the market has re-opened more widely as bonds have recovered 75% of the value lost since March. GlaxoSmithKline was able to achieve a coupon of just 4% at the beginning of June for a 20-year deal, and a slew of hybrid issues—perpetual subordinated debt that is counted as equity by rating agencies—from corporates such as the world’s biggest sugar producer Südzucker have proved that investors’ reluctance to buy lower-rated credit was an aberration. Part of the reason for this is practical: Inflows remain strong, and they have to be invested somewhere. Also, fears of a rate rise in the US have receded, meaning the carry trade is once again economical.
From an issuer’s perspective the introduction of the EU prospectus directive on July 1 has been a boon to issuance. “It is concentrating issuers’ minds on their deal timetables,” says Eirik Winter, European co-head of fixed-income capital markets at Citigroup in London. “They know that if they don’t do a deal shortly, they will have to spend some time preparing new documentation and then have to wait their turn once the market opens after the summer.”
In addition, treasurers have realized after the fright of the months after March that credit markets can easily turn bad and lock them out. “It’s been a rude awakening,” says ABN AMRO’s Bell. “Corporate treasurers are now cognizant of volatility in a way they were not in March. They’ve also realized that on a four-year horizon absolute yields are unbelievably low.” But the way in which issuers are approaching the market has changed. As Citigroup’s Winter notes, the new watchword among issuers—in relation to market conditions, timing or investors’ demands on tenor, pricing or structure—is responsiveness.
|